Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 20/20 | 1.00 |
| ▸ | ITGAV | P06756 | 20/20 | 1.00 |
| ▸ | ITGA2B | P08514 | 19/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7969198 | 1.00 | ITGB3 (1.00) | ITGB3ITGAVITGA2B | |
| SCHEMBL30856549 | 1.00 | ITGB3 (1.00) | ITGB3ITGAVITGA2B | |
| Trifluoroacetic Acid SCHEMBL3743186 | 0.96 | ITGB3 (0.92) | ITGB3ITGAVITGA2B | |
| Trifluoroacetic Acid SCHEMBL3743175 | 0.96 | ITGB3 (0.92) | ITGB3ITGAVITGA2B | |
| SCHEMBL7969271 | 0.94 | ITGB3 (1.00) | ITGB3ITGAVITGA2B | |
| SCHEMBL7982808 | 0.94 | ITGB3 (1.00) | ITGB3ITGAVITGA2B | |
| SCHEMBL14289059 | 0.92 | ITGB3 (0.84) | ITGB3ITGAVITGA2B | |
| SCHEMBL14289052 | 0.92 | ITGB3 (0.84) | ITGB3ITGAVITGA2B | |
| SCHEMBL14450438 | 0.91 | ITGB3 (1.00) | ITGB3ITGAVITGA2B | |
| Trifluoroacetic Acid SCHEMBL7980483 | 0.90 | ITGB3 (0.93) | ITGB3ITGAVITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4637731-A1 | COMBINATION THERAPY FOR TREATING CANCER | GILEAD SCIENCES, INC. (US) | 2025-10-29 | — | — | EP | claimed |
| WO-2024137442-A1 | COMBINATION THERAPY FOR TREATING CANCER | GILEAD SCIENCES, INC. (US) | 2024-06-27 | — | — | WO | claimed |
| US-11697812-B2 | Methods and compositions for the specific inhibition of transthyretin (TTR) by double-stranded RNA | DICERNA PHARMACEUTICALS, INC. (US) | 2023-07-11 | — | — | US | claimed |
| US-11359203-B2 | Therapeutic inhibition of lactate dehydrogenase and agents therefor | DICERNA PHARMACEUTICALS, INC. (US) | 2022-06-14 | — | — | US | claimed |
| EP-3609434-B1 | MEDICAL DEVICES COATED WITH POLYDOPAMINE AND ANTIBODIES | ORBUSNEICH MEDICAL PTE LTD (SG) | 2026-05-20 | — | — | EP | disclosed |
| EP-4637731-A1 | COMBINATION THERAPY FOR TREATING CANCER | GILEAD SCIENCES, INC. (US) | 2025-10-29 | — | — | EP | disclosed |
| EP-3461809-B1 | TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS INC (US) | 2025-03-26 | — | — | EP | disclosed |
| CN-119630399-A | Periostin-mediated disease and prophylactic or therapeutic agent for itching associated with the disease | 国立大学法人佐贺大学 | 2025-03-14 | — | — | CN | disclosed |
| WO-2024137442-A1 | COMBINATION THERAPY FOR TREATING CANCER | GILEAD SCIENCES, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024024915-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR PERIOSTIN-MEDIATED DISEASE AND PRURITUS ASSOCIATED THEREWITH | 国立大学法人佐賀大学 | 2024-02-01 | — | — | WO | disclosed |
| US-11873493-B2 | Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA | DICERNA PHARMACEUTICALS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-11773390-B2 | Methods and compositions for the specific inhibition of Complement Component 5(C5) by double-stranded RNA | DICERNA PHARMACEUTICALS, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| CN-115137880-A | Medical equipment with coating | 祥丰医疗私人有限公司 | 2022-10-04 | — | — | CN | disclosed |
| CN-110545754-B | Medical device with coating and use for treating or preventing vascular disorders | 祥丰医疗私人有限公司 | 2022-06-28 | — | — | CN | disclosed |
| US-11359203-B2 | Therapeutic inhibition of lactate dehydrogenase and agents therefor | DICERNA PHARMACEUTICALS, INC. (US) | 2022-06-14 | — | — | US | disclosed |
| US-11278504-B1 | Treatment of a lionfish sting and formulations for use thereof | PTERO TECH INC. (CA) | 2022-03-22 | — | — | US | disclosed |
| CN-107257858-B | Therapeutic inhibition of lactate dehydrogenase and reagents therefor | 戴瑟纳制药公司 | 2022-03-08 | — | — | CN | disclosed |
| US-20090311266-A1 | Inhibitors of the endothelin signalling pathway and alphavbeta3 integrin receptor antagonists for combination therapy | BASF AKTIENGESELLSCHAFT (DE) | 2009-12-17 | — | — | US | disclosed |
| EP-1239877-B1 | COMPOSITION COMPRISING A TNF-ALPHA INHIBITOR AND AN INTEGRIN ALPHAVBETA3 RECEPTOR ANTAGONIST | ABBOTT GMBH & CO KG (DE) | 2008-01-09 | — | — | EP | disclosed |
| US-20060159678-A1 | Modulators of cytokine mediated signaling pathways and integrin alphabeta3 receptor antagonists for combination therapy | GENESTE HERVE | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11278504-B1 | Treatment of a lionfish sting and formulations for use thereof | P2RX3, P2RX7, P2RX5 | ITGB3 830/4885ITGAV 2037/4885ITGA2B 1526/4885 |
| US-20060159678-A1 | Modulators of cytokine mediated signaling pathways and integrin alphabeta3 receptor antagonists for combination therapy | ITGB3, IL6ST, IL1RN | ITGB3 1/4885ITGAV 11/4885ITGA2B 10/4885 |
| US-20090311266-A1 | Inhibitors of the endothelin signalling pathway and alphavbeta3 integrin receptor antagonists for combination therapy | EDNRB, EDNRA, ITGB3 | ITGB3 3/4885ITGAV 4/4885ITGA2B 12/4885 |
| US-11697812-B2 | Methods and compositions for the specific inhibition of transthyretin (TTR) by double-stranded RNA | TTR, RNASE1, SARNP | ITGB3 4011/4885ITGAV 3062/4885ITGA2B 3818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.